TransMedics Group, Inc. (NASDAQ:TMDX) Shares Sold by Moody Aldrich Partners LLC
TransMedics Group, Inc. (NASDAQ:TMDX) Shares Sold by Moody Aldrich Partners LLC
Moody Aldrich Partners LLC cut its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX – Get Rating) by 43.3% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 106,798 shares of the company's stock after selling 81,523 shares during the quarter. Moody Aldrich Partners LLC owned 0.38% of TransMedics Group worth $3,359,000 as of its most recent filing with the SEC.
据纳斯达克最新披露的消息称,该公司在第二季度将其持有的TransMedics Group,Inc.(股票代码:TMDX-GET)的股票头寸削减了43.3%。该基金在本季度出售了81,523股后,持有该公司106,798股股票。根据TransMedics集团最近向美国证券交易委员会提交的文件,Moody Aldrich Partners LLC持有该集团0.38%的股份,价值3,359,000美元。
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Swiss National Bank raised its holdings in TransMedics Group by 7.7% during the first quarter. Swiss National Bank now owns 59,100 shares of the company's stock worth $1,592,000 after purchasing an additional 4,200 shares during the last quarter. Divisadero Street Capital Management LP purchased a new position in TransMedics Group during the first quarter worth $323,000. Signature Wealth Management Partners LLC purchased a new position in TransMedics Group during the first quarter worth $329,000. Oppenheimer & Co. Inc. purchased a new position in TransMedics Group during the first quarter worth $257,000. Finally, Boston Partners increased its position in TransMedics Group by 13.6% during the first quarter. Boston Partners now owns 18,811 shares of the company's stock worth $507,000 after buying an additional 2,251 shares in the last quarter. 81.46% of the stock is owned by institutional investors and hedge funds.
其他对冲基金和其他机构投资者最近也买卖了该公司的股票。瑞士国家银行在第一季度增持了TransMedics Group 7.7%的股份。瑞士国家银行现在持有59,100股该公司股票,价值1,592,000美元,在上个季度又购买了4,200股。Divisadero Street Capital Management LP在第一季度购买了TransMedics Group的一个新头寸,价值32.3万美元。Signature Wealth Management Partners LLC在第一季度购买了TransMedics Group的一个新头寸,价值32.9万美元。Oppenheimer&Co.Inc.在第一季度购买了TransMedics Group价值25.7万美元的新头寸。最后,波士顿合伙公司在第一季度将其在TransMedics Group的头寸增加了13.6%。波士顿合伙公司现在持有18,811股该公司股票,价值507,000美元,上个季度又购买了2,251股。81.46%的股票由机构投资者和对冲基金持有。
Analysts Set New Price Targets
分析师设定新的价格目标
TMDX has been the subject of several recent research reports. Cowen raised their price target on TransMedics Group from $45.00 to $50.00 in a research report on Tuesday, August 2nd. JPMorgan Chase & Co. raised TransMedics Group from a "neutral" rating to an "overweight" rating and raised their price target for the stock from $26.00 to $48.00 in a research report on Tuesday, August 2nd. Cowen raised their price target on TransMedics Group from $39.00 to $45.00 and gave the stock an "outperform" rating in a research report on Tuesday, July 26th. Oppenheimer raised their price target on TransMedics Group from $40.00 to $45.00 and gave the stock an "outperform" rating in a research report on Tuesday, August 2nd. Finally, Morgan Stanley lifted their price objective on TransMedics Group from $34.00 to $37.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 3rd. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $46.00.
TMDX是最近几份研究报告的主题。考恩在8月2日星期二的一份研究报告中将TransMedics Group的目标价从45.00美元上调至50.00美元。摩根大通在8月2日周二的一份研究报告中将TransMedics Group的评级从中性上调至增持,并将该股目标价从26.00美元上调至48.00美元。考恩在7月26日(周二)的一份研究报告中将TransMedics Group的目标价从39.00美元上调至45.00美元,并给予该股“跑赢大盘”的评级。8月2日,周二,奥本海默在一份研究报告中将TransMedics Group的目标价从40.00美元上调至45.00美元,并给予该股“跑赢大盘”的评级。最终,摩根士丹利在8月3日星期三的一份研究报告中将他们对TransMedics Group的目标价从34美元上调至37美元,并给予该公司“同等权重”的评级。一名分析师对该股的评级为持有,六名分析师对该股的评级为买入。根据MarketBeat.com的数据,该公司目前的平均评级为“中等买入”,共识目标价为46.00美元。
Insider Buying and Selling at TransMedics Group
TransMedics Group的内幕买卖
TransMedics Group Trading Down 2.7 %
TransMedics集团股价下跌2.7%
Shares of NASDAQ:TMDX opened at $41.68 on Friday. The company has a quick ratio of 3.41, a current ratio of 4.18 and a debt-to-equity ratio of 0.70. TransMedics Group, Inc. has a 52 week low of $10.00 and a 52 week high of $56.41. The business has a fifty day simple moving average of $45.92 and a 200-day simple moving average of $33.42.
新浪纳斯达克:TMDX上周五开盘报41.68美元。该公司的速动比率为3.41,流动比率为4.18,债务权益比率为0.70。TransMedics Group,Inc.的52周低点为10.00美元,52周高位为56.41美元。该业务的50日简单移动均线切入位为45.92美元,200日简单移动均线切入位为33.42美元。
TransMedics Group (NASDAQ:TMDX – Get Rating) last posted its quarterly earnings results on Monday, August 1st. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.09). TransMedics Group had a negative net margin of 92.76% and a negative return on equity of 74.20%. The firm had revenue of $20.52 million for the quarter, compared to analysts' expectations of $16.26 million. During the same period last year, the firm posted ($0.39) EPS. On average, sell-side analysts predict that TransMedics Group, Inc. will post -1.57 EPS for the current year.
跨医药集团(纳斯达克代码:TMDX-GET Rating)最近一次公布季度收益是在8月1日星期一。该公司公布本季度每股收益(EPS)为0.41美元,低于分析师一致预期的0.32美元和0.09美元。TransMedics集团的净利润率为负92.76%,净资产回报率为负74.20%。该公司当季营收为2,052万美元,高于分析师预期的1,626万美元。去年同期,该公司公布的每股收益为0.39美元。卖方分析师平均预测,TransMedics Group,Inc.本年度每股收益将达到1.57欧元。
TransMedics Group Company Profile
TransMedics集团公司简介
(Get Rating)
(获取评级)
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
TransMedics Group,Inc.是一家商业阶段的医疗技术公司,致力于为美国和国际上的终末期器官衰竭患者改造器官移植疗法。该公司提供器官护理系统(OCS),这是一种便携式器官灌流、优化和监测系统,利用其专有和定制的技术来复制人体外捐赠器官的近生理条件。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on TransMedics Group (TMDX)
- Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- 2 Semiconductor Stocks To Watch For Reversals
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
- 免费获取StockNews.com关于TransMedics Group(TMDX)的研究报告
- 华尔街对Datadog的热情会带来巨大的收益吗?
- MarketBeat:回顾一周9/19-9/23
- 为什么特斯拉的股票保持弹性?
- 需要关注的2只半导体类股走势逆转
- CrowdStrike是否会从增加每股收益指引中获得提振?
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.
接受TransMedics Group Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯,接收TransMedics Group和相关公司的最新新闻和分析师评级的每日摘要。